Compounds that Target Sigma-1 Receptor Offer Promise in Battling Alzheimer’s, Says Anavex

Compounds that Target Sigma-1 Receptor Offer Promise in Battling Alzheimer’s, Says Anavex
New York-based Anavex Life Sciences presented data at the recent 13th International Conference on Alzheimer’s & Parkinson’s Diseases in Vienna showing that its compounds binding to the sigma-1 receptor hold promise in treating Alzheimer’s disease. Besides the well-known accumulation of amyloid beta peptide and the formation of senile plaques, researchers have extensively described the brain inflammation and reduced synaptogenesis (the formation

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *